ALNY vs KMT · P/E 76, rev $1.29B vs P/E 17, rev $2.36B
Alnylam Pharmaceuticals Inc (ALNY) versus Kennametal Inc (KMT) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Kennametal Inc (KMT) is a tools & accessories company listed on US.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported KMT revenue for 2026-06-30 was $2.36B. Net income was $342.4M. Revenue was up 19.8% from 2025-06-30 to 2026-06-30. KMT currently screens at market cap $1.85B and trailing P/E 17.3.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. KMT currently screens at market cap $1.85B and trailing P/E 17.3.
Not investment advice. Open the ALNY and KMT stock pages for the full models.
Not investment advice.